While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action.
Feature|Articles|September 30, 2026
Life Sciences Compliance: Diagnosis Incomplete
Author(s)Avi Pardo
Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
Advertisement
Advertisement
Life sciences companies operate under some of the most exacting regulatory scrutiny of any industry. From drug development and clinical trials to promotional practices and HCP engagement, pharmaceutical, biotechnology and medical device companies invest enormous resources in compliance: building policies, training employees, monitoring marketing claims and documenting every interaction that touches a regulated process.
Related to this article
New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.
Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as interim co-CEOs.
Novo licensed Hengrui's once-weekly oral GLP-1/GIP dual agonist HRS-1596 in a deal worth up to $2.6 billion, while AstraZeneca invested $2 billion in Summit Therapeutics to pair ivonescimab with its antibody-drug conjugate portfolio.
FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
Advertisement
Advertisement